Certified by Founder Lodge
Nextech Invest
Switzerland - Zurich
INVESTOR
1 Disclosed Funding Rounds $122,000,000
26 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. We focus almost exclusively on oncology therapeutics, and on helping to drive value
Company | Date | Round | Raised |
---|---|---|---|
Mariana Oncology | September, 08 ,2023 | Series B | $175,000,000 |
Mariana Oncology | September, 08 ,2023 | Series B | $175,000,000 |
Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
IDRx | August, 02 ,2022 | Series A | $122,000,000 |
Flare Therapeutics | March, 23 ,2023 | Series B | $123,000,000 |
Atavistik Bio | December, 26 ,2023 | Unknown | $40,000,000 |
Atavistik Bio | December, 26 ,2023 | Unknown | $40,000,000 |
Delphia Therapeutics | May, 07 ,2024 | Series A | $67,000,000 |
Boundless Bio | May, 17 ,2023 | Series C | $100,000,000 |
FogPharma | March, 05 ,2024 | Series E | $145,000,000 |
FogPharma | March, 05 ,2024 | Series E | $145,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Mariana Oncology | September, 08 ,2023 | Series B | $175,000,000 |
Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
Delphia Therapeutics | May, 07 ,2024 | Series A | $67,000,000 |
Atavistik Bio | December, 26 ,2023 | Unknown | $40,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Delphia Therapeutics | May, 07 ,2024 | Series A | $67,000,000 |
Alpha-9 Oncology | October, 24 ,2024 | Series C | $175,000,000 |
FogPharma | March, 05 ,2024 | Series E | $145,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Alterome Therapeutics, Inc | April, 09 ,2024 | Series B | $132,000,000 |
Delphia Therapeutics | May, 07 ,2024 | Series A | $67,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Alpha-9 Oncology | October, 24 ,2024 | Series C | $175,000,000 |